FDA rejects AcelRx's Zalviso By: MarketMinute.com Stock News July 28, 2014 at 15:42 PM EDT The Food and Drug Administration rejected AcelRx Pharmaceuticals Inc.'s (Nasdaq: ACRX) needle-free pain medication device Zalviso sending the stock price plummeting $4.26 to $6.57. Related Stocks: Acelrx Pharmaceutica